Acquired Company

Sevion Therapeutics, Inc. and Eloxx Pharmaceuticals completed the acquisition transaction effective December 19, 2017; Eloxx stock was converted into Sevion common stock and the combined company began trading under the Eloxx name on December 20, 2017.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of RNA-modulating drugs in the United States. The company develops ELX-02, which is in phase II clinical trial for the treatment of nonsense mutation alport syndrome; ZKN013, which is in investigation phase for the treatment of nonsense mutation recessive dystrophic and junctional epidermolysis bullosa; and ZKN013, which is in investigation phase for the treatment of nonsense mutation familial adenomatous polyposis. It also offers platform technologies, including Turbo-ZM and Ribosome Modulating Agents; and Eukaryotic Ribosomal Selective Glycosides for the treatment of rare and ultra-rare premature stop codon diseases. The company is headquartered in Watertown, Massachusetts. Show more

Location: 480 Arsenal Way, Watertown, MA, 02472, United States | Website: https://www.eloxxpharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

314

52 Wk Range

$0.00 - $0.75

Previous Close

$0.00

Open

$0.00

Volume

1,450

Day Range

$0.00 - $0.00

Enterprise Value

983.3K

Cash

4.775M

Avg Qtr Burn

-4.498M

Insider Ownership

5.82%

Institutional Own.

0.00%

Qtr Updated

09/30/23

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ELX-02 Details Lung disease, Cystic fibrosis, Glabellar lines	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELX-02 Details Rare genetic disease, Alport Syndrome	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ZKN-013 Details Rare genetic disease, Junctional epidermolysis bullosa, Recessive dystrophic epidermolysis bullosa	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELX-02 Details Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.